OCIAD2

OCIAD2 is a dual-localized protein found in mitochondria and early endosomes whose conserved double helical motif within the OCIA domain mediates its subcellular targeting and protein-protein interactions, linking mitochondrial bioenergetics to membrane signaling (PMID:29743632, PMID:35080992). At the mitochondrial inner membrane it acts as an assembly factor specifically required for dimeric complex III (CIII2) and the III2+IV supercomplex, with its loss reducing CIII enzymatic activity and producing abnormal mitochondrial morphology (PMID:35080992). Through its OCIA double helical motif OCIAD2 engages a series of signaling partners — STAT3, IQGAP1, and integrin β1 — to drive JAK/STAT3 and PI3K/AKT/FAK signaling, promoting cell migration; integrin β1 is stabilized by OCIAD2 binding to SNX17, which routes the integrin through endosomal recycling to lipid raft membrane regions and away from lysosomal degradation (PMID:29743632, PMID:41655222, PMID:41197887). OCIAD2 also stimulates γ-secretase activity by binding nicastrin, enhancing lipid raft localization of the complex and APP processing toward Aβ production without affecting Notch cleavage (PMID:24270855). By coupling fatty acid oxidation and OXPHOS to TGFβ signaling, OCIAD2 further modulates mitochondrial metabolism and epithelial-to-mesenchymal transition [PMID:bio_10.1101_2025.11.10.687537, PMID:40690206]. Independently, OCIAD2 serves as a proviral host cofactor for HCV replication via direct interaction with the viral NS4B protein in the replication complex (PMID:34371038).

1. 2013 High

   Established the first molecular function for OCIAD2 by showing it activates γ-secretase, addressing how an uncharacterized protein could influence amyloidogenic APP processing.

   Evidence Genome-wide functional cDNA screen, co-IP, lipid raft fractionation, and a cell-permeable inhibitory peptide in cell lines

   PMID:24270855

   Open questions at the time

   • No structural basis for the nicastrin interaction
   • Selectivity for APP over Notch not mechanistically explained
   • In vivo relevance to amyloid pathology untested
2. 2017 Medium

   Placed OCIAD2 upstream of AKT/FAK signaling in cancer, addressing whether it functions as a signaling regulator beyond γ-secretase.

   Evidence siRNA knockdown, clonogenic/migration/invasion assays, and AKT inhibitor epistasis in HCC cell lines

   PMID:28911005

   Open questions at the time

   • Direct molecular partner linking OCIAD2 to AKT not identified
   • Knockdown rather than clean genetic loss
   • Single tumor type
3. 2018 High

   Defined the OCIA double helical motif as the determinant of OCIAD2 localization and interactions and connected it to STAT3 activation, addressing the structure-function basis of its dual roles.

   Evidence Subcellular fractionation/IF, reciprocal co-IP, domain disruption, and KD/OE migration assays

   PMID:29743632

   Open questions at the time

   • No experimental structure of the OCIA domain
   • Mechanism by which the motif drives both mitochondrial and endosomal targeting unresolved
4. 2021 Medium

   Identified OCIAD2 as a proviral host cofactor, addressing how it is co-opted by HCV.

   Evidence siRNA screen, co-IP mapping NS4B/NS5A/PREB interactions, and a binding-deficient mutant rescue in HCV replication assays

   PMID:34371038

   Open questions at the time

   • Structural detail of the NS4B interface unknown
   • How OCIAD2 mechanistically supports replication complex function unclear
   • Single lab
5. 2022 High

   Defined OCIAD2 as a mitochondrial inner membrane complex III assembly factor, addressing its native bioenergetic function.

   Evidence CRISPR-Cas9 knockout in HEK293, co-IP with ETC proteins, BN-PAGE, and CIII enzymatic assay

   PMID:35080992

   Open questions at the time

   • Step in the CIII assembly pathway at which OCIAD2 acts not defined
   • No structural model of OCIAD2 within assembly intermediates
   • Relationship between assembly role and signaling roles unexplored
6. 2025 Medium

   Linked OCIAD2 to IQGAP1 and to mitochondrial/metabolic control, addressing how it suppresses apoptosis and sustains PI3K/AKT signaling.

   Evidence IP-MS, co-IP validation, mitochondrial function and apoptosis assays, and xenografts in PDAC; plus Seahorse metabolic assays in lung adenocarcinoma

   PMID:40690206 PMID:41197887

   Open questions at the time

   • Whether metabolic effects derive from the CIII assembly role versus signaling not separated
   • Direct versus indirect IQGAP1 binding interface not mapped
7. 2025 Medium

   Connected OCIAD2 to TGFβ-coupled fatty acid oxidation during EMT and developmental differentiation, addressing how it integrates metabolic and signaling cues.

   Evidence CRISPR-Cas9 KO/OE in hESCs, transcriptomics, and pharmacological FAO restoration (preprint)

   PMID:bio_10.1101_2025.11.10.687537

   Open questions at the time

   • Preprint, not yet peer-reviewed
   • Direct molecular link between OCIAD2 and TGFβ transcription undefined
   • Causality between hyperfused mitochondria and differentiation defect unresolved
8. 2026 High

   Resolved a trafficking mechanism by which OCIAD2 stabilizes integrin β1, addressing how it sustains FAK-PI3K-AKT-mTOR signaling and drug resistance.

   Evidence Co-IP/MS, lysosomal degradation and lipid raft fractionation assays, signaling immunoblots, and shRNA silencing with xenografts in HNSCC

   PMID:41655222

   Open questions at the time

   • Whether SNX17 recruitment uses the OCIA double helical motif not stated
   • How endosomal OCIAD2 pool relates to mitochondrial pool unclear

• It remains unknown how OCIAD2's mitochondrial complex III assembly function mechanistically relates to its endosomal trafficking and signaling activities, and whether these reflect distinct subpopulations or a single integrating mechanism.
• No unifying structural or biochemical model spanning both compartments
• No experimental structure of the OCIA domain
• Substrate/client specificity of the assembly factor role undefined